Supported by

With financial support by the EU through the CrossRoads Vlaanderen-Nederland programme, ImmuneSpec and RiboPro are joining forces to investigate the immunogenicity caused by mRNA therapies. This funding enables the integration of ImmuneSpec’s advanced immunopeptidomics expertise with RiboPro’s know-how in mRNA design, driving forward new insights into mRNA-based therapeutics.